Why Invest?

Cognetivity Neurosciences (CSE:CGN OTCQB:CGNSF), a medical technology company founded at the University of Cambridge, UK, has developed a five-minute cognitive function test, powered by artificial intelligence. Its Integrated Cognitive Assessment (ICA) is an easy-to-use, sensitive, reliable and hugely scalable test that represents a major advance in monitoring brain health.

Delivered via touchscreen devices and the web, the ICA provides a unique end-to-end solution for measuring cognition. It allows early detection of neurological issues, leading to better outcomes for patients and reduced costs for healthcare systems.

Cognetivity is commercialising the ICA in medical and corporate markets in the USA, Europe, the Middle East and elsewhere. With a global estimated market size for cognitive assessment and training expected to reach $11.4 billion by 2026, rising at a market growth of 26.6% CAG, and more than 350 million over 55s in USA, EU and Middle East, Cognetivity’s unique technology is poised to transform the way that brain health is measured and to generate substantial revenue in the coming years.

Our partners

We work with world-leading organisations, from global universities to leading research organisations.

Latest news and updates

通过人工智能应用 年长者可自行检测是否失智

News | No Comments

Powering Rapid Cognitive Analysis with AI

News | No Comments
Dr. Tom Sawyer, CFO at Cognetivity Neurosciences, sat down with me to discuss the benefits of AI-driven…

Why Your Product Should Generate Revenue Versus Reduce Costs: Interview with Cognetivity CEO Sina Habibi

News | No Comments
Cognetivity Neurosciences Co-founder and CEO Sina Habibi met his business partner Seyed-Mahdi Khaligh-Razavi while obtaining his Ph.D. at the University…

Looking to download our Investor Materials?

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

We’re looking forward to hearing from you.

Talk to a member of the team